Technology

Nucor to Acquire Manufacturer of High-Performance Commercial Doors

Published

2 years ago

June 3, 2024

CHARLOTTE, N.C., June 3, 2024 /PRNewswire/ — Nucor Corporation (NYSE: NUE) announced today that it has entered into an agreement to acquire Rytec Corporation, a manufacturer and seller of high-speed, high-performance commercial doors. The all-cash transaction is valued at $565 million, which represents approximately 12.5x Rytec’s estimated 2024 EBITDA. With over 300 teammates operating out of two manufacturing facilities in Wisconsin, Rytec is widely considered to be the pre-eminent brand for high-performance commercial doors.

“Rytec is a leader in high-performance commercial doors and serves several growing end-user markets. This acquisition further executes our strategy to expand beyond our core steelmaking businesses into related downstream businesses. Adding high-performance doors will create cross-selling opportunities with other Nucor businesses and greatly expand Nucor’s product portfolio serving the commercial arena,” said Leon Topalian, Chair, President and Chief Executive Officer of Nucor. “Rytec has a strong cultural fit with Nucor, and we are excited to welcome the Rytec teammates to the Nucor family.”

Rytec produces high-speed Spiral® rigid rolling doors for warehouses, manufacturing facilities, auto dealerships, and parking garages, as well as durable fabric doors for cold storage/food and beverage, manufacturing, and clean room applications. The company has a strong focus on product development and has invested significantly in technology and automation to improve quality, increase efficiency, and enhance safety.

“We are excited to work with the incredible team at Rytec. Their products are a natural platform for expanding Nucor’s overhead door product suite. Rytec has established itself as the premier brand in high-performance commercial doors, with a strong reputation for quality and best-in-class customer service. The combination of Rytec with C.H.I. Overhead Doors will create an overhead door platform that will deliver superior product breadth and solutions to Nucor’s commercial customers,” said Chad Utermark, Executive Vice President of New Markets and Innovation for Nucor.

About Nucor
Nucor and its affiliates are manufacturers of steel and steel products, with operating facilities in the United States, Canada and Mexico. Products produced include: carbon and alloy steel — in bars, beams, sheet and plate; hollow structural section tubing; electrical conduit; steel racking; steel piling; steel joists and joist girders; steel deck; fabricated concrete reinforcing steel; cold finished steel; precision castings; steel fasteners; metal building systems; insulated metal panels; overhead doors; steel grating; wire and wire mesh; and utility structures. Nucor, through The David J. Joseph Company and its affiliates, also brokers ferrous and nonferrous metals, pig iron and hot briquetted iron/direct reduced iron; supplies ferro-alloys; and processes ferrous and nonferrous scrap. Nucor is North America’s largest recycler.

Forward-Looking Statements
Certain statements contained in this news release are “forward-looking statements” that involve risks and uncertainties which we expect will or may occur in the future and may impact our business, financial condition and results of operations. The words “anticipate,” “believe,” “expect,” “intend,” “project,” “may,” “will,” “should,” “could” and similar expressions are intended to identify those forward-looking statements. These forward-looking statements reflect the Company’s best judgment based on current information, and, although we base these statements on circumstances that we believe to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance, and actual results may vary materially from the projected results and expectations discussed in this news release. Factors that might cause the Company’s actual results to differ materially from those anticipated in forward-looking statements include, but are not limited to: (1) competitive pressure on sales and pricing, including pressure from imports and substitute materials; (2) U.S. and foreign trade policies affecting steel imports or exports; (3) the sensitivity of the results of our operations to general market conditions, and in particular, prevailing market steel prices and changes in the supply and cost of raw materials, including pig iron, iron ore and scrap steel; (4) the availability and cost of electricity and natural gas, which could negatively affect our cost of steel production or result in a delay or cancellation of existing or future drilling within our natural gas drilling programs; (5) critical equipment failures and business interruptions; (6) market demand for steel products, which, in the case of many of our products, is driven by the level of nonresidential construction activity in the United States; (7) impairment in the recorded value of inventory, equity investments, fixed assets, goodwill or other long-lived assets; (8) uncertainties and volatility surrounding the global economy, including excess world capacity for steel production, inflation and interest rate changes; (9) fluctuations in currency conversion rates; (10) significant changes in laws or government regulations affecting environmental compliance, including legislation and regulations that result in greater regulation of greenhouse gas emissions that could increase our energy costs, capital expenditures and operating costs or cause one or more of our permits to be revoked or make it more difficult to obtain permit modifications; (11) the cyclical nature of the steel industry; (12) capital investments and their impact on our performance; (13) our safety performance; (14) our ability to integrate businesses we acquire; and (15) the impact of the COVID-19 pandemic, any variants of the virus, and any other similar pandemic or public health situation. These and other factors are discussed in Nucor’s regulatory filings with the United States Securities and Exchange Commission, including those in “Item 1A. Risk Factors” of Nucor’s Annual Report on Form 10-K for the year ended December 31, 2023. The forward-looking statements contained in this news release speak only as of this date, and Nucor does not assume any obligation to update them, except as may be required by applicable law.

View original content:https://www.prnewswire.com/news-releases/nucor-to-acquire-manufacturer-of-high-performance-commercial-doors-302161960.html

SOURCE Nucor Corporation

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

28 minutes ago

April 23, 2026

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

28 minutes ago

April 23, 2026

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

28 minutes ago

April 23, 2026

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system, helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company